Search Results

13,084 Results for "affimed gmbh".

Sort By

Press Releases

Affimed Reports Third Quarter 2024 Financial Results & Business Update

November 15, 2024
·
13 min read
Press Releases

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

December 18, 2024
·
9 min read
Business

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results and provided an update on clinical and corporate progress for the quarter ended March 31, 2024.

June 12, 2024
·
15 min read
Press Releases

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

November 6, 2024
·
1 min read
Affimed Announces Annual General Meeting of Shareholders - May 28, 2024

Affimed N.V. announced that its 2024 Annual General Meeting of Shareholders will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.

May 28, 2024
·
1 min read
Press Releases

Affimed to Present at the Cantor Global Healthcare Conference 2024

September 10, 2024
·
1 min read
Press Releases

Niterra Ventures Company Invests $18M Additional Funding in Neoplas Med GmbH

November 25, 2024
·
4 min read
Press Releases

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

December 9, 2024
·
5 min read
Business

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024.

June 5, 2024
·
1 min read
Deals

Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.

June 13, 2024
·
3 min read